Two highly promising strategies designed to harness the immune system to treat patients with DLBCL are therapeutic blockade of the PD-1/PD-L1 pathway and chimeric antigen receptor (CAR) T cell therapy. Here, CD274 is linked to diffuse large B-cell lymphoma.